Real-World Outcomes of Patients with Refractory or Relapsed
FLT3-ITD mutation
acute myeloid leukemia
primary induction failure
relapse
tyrosine kinase inhibitors
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Jul 2020
24 Jul 2020
Historique:
received:
08
06
2020
revised:
20
07
2020
accepted:
22
07
2020
entrez:
30
7
2020
pubmed:
30
7
2020
medline:
30
7
2020
Statut:
epublish
Résumé
Two recent phase 3 trials showed that outcomes for relapsed/refractory (R/R)
Identifiants
pubmed: 32722211
pii: cancers12082044
doi: 10.3390/cancers12082044
pmc: PMC7465142
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Leukemia. 2011 Jun;25(6):939-44
pubmed: 21331073
Leukemia. 2010 Aug;24(8):1437-44
pubmed: 20535150
Blood Cancer J. 2017 Nov 29;7(12):635
pubmed: 29184070
Am J Hematol. 2018 Jun 15;:
pubmed: 29905379
Blood. 2017 Jun 29;129(26):3403-3406
pubmed: 28546144
J Clin Oncol. 2017 Mar 20;35(9):934-946
pubmed: 28297624
Nature. 2012 Apr 15;485(7397):260-3
pubmed: 22504184
Int J Mol Sci. 2019 Jul 12;20(14):
pubmed: 31336846
N Engl J Med. 2008 May 1;358(18):1909-18
pubmed: 18450602
Cancers (Basel). 2020 Mar 25;12(4):
pubmed: 32218221
N Engl J Med. 2019 Oct 31;381(18):1728-1740
pubmed: 31665578
Genes Cancer. 2010 Oct;1(10):1021-32
pubmed: 21779428
Blood. 2019 Feb 21;133(8):840-851
pubmed: 30563875
Ann Intern Med. 1993 Feb 1;118(3):201-10
pubmed: 8417638
Blood. 1998 Oct 1;92(7):2322-33
pubmed: 9746770
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Lancet Oncol. 2019 Jul;20(7):984-997
pubmed: 31175001
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Blood. 2002 Jul 1;100(1):59-66
pubmed: 12070009
N Engl J Med. 2017 Aug 3;377(5):454-464
pubmed: 28644114